ERBB2 and breast carcinoma: On the other hand, the immune checkpoint, programmed cell-death ligand-1 (PD-L1) is significantly expressed in triple-negative followed by the HER2-positive breast cancer subtypes [24–28]; thus, indicating that HER2-positive breast cancer is immunogenic [29].